New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 28, 2014
05:35 EDTLRLCY, VRX, NSRGYNestle creates Nestle Skin Health with acquisition of Valeant assets for $1.4B
NestlÚ (NSRGY) announced it would extend its activities to include the field of specialized medical skin treatments through the creation of NestlÚ Skin Health S.A. The foundation for the company would be Galderma, the 50/50 joint venture with L'Oreal (LRLCY), which would become fully-owned by NestlÚ. BŘbchen, the company's existing infant skin care business would be merged into the new entity. The acquisition of Galderma is awaiting final regulatory clearance. NestlÚ is announcing it will reinforce NestlÚ Skin Health with the acquisition from the Canadian firm Valeant Pharmaceuticals (VRX) of the full rights to commercialize several key aesthetic dermatology products in the U.S. and Canada for $1.4B in cash. The two markets together represent more than half of the fast-growing medical aesthetics market around the world. Galderma already commercializes the products included in this transaction outside those markets. NestlÚ is acquiring the full rights to commercialize in the U.S. and Canada Restylane, Perlane and Emervel, products used for corrective facial aesthetic treatments, and Dysport, an aesthetic dermatology treatment. It will also acquire the full rights to Sculptra, a unique treatment for aesthetic and medical uses in the U.S., Canada and many markets around the world.
News For NSRGY;VRX;LRLCY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 4, 2015
17:56 EDTVRXAckman says Valeant also an 'underrated platform' company
Subscribe for More Information
12:41 EDTVRXAckman says Zoetis a 'great' business on standalone basis
Subscribe for More Information
12:38 EDTVRXAckman says 'not sure' Valeant is best acquirer of Zoetis
Subscribe for More Information
April 30, 2015
07:43 EDTVRXValeant named a new Top Pick at Barclays
Barclay's Doug Taso raised Valeant's (VRX) price target to $275 from $230 and named its his Top Pick following the Q1 report and recent management meetings that increased his confidence that earnings growth can be higher than consensus expectations. Management inferred that the Marathon and Salix (SLXP) acquisitions will drive much higher gross margins and the analyst believes the deal pipeline remains strong and dealmaking should continue. The firm has an Overweight rating on Valeant shares.
06:47 EDTVRXValeant price target raised to $271 from $222 at Cantor
Cantor increased its price target on Valeant after the company reported stronger than expected Q1 results. The firm thinks the company's U.S. sales could approach $7.4B this year and surpass $10B in 2016. It keeps a Buy rating on the shares.
April 29, 2015
06:13 EDTVRXValeant announces CFO succession plan
Subscribe for More Information
06:12 EDTVRXValeant sees accretion from Salix acquisition over 20% in FY16
Subscribe for More Information
06:11 EDTVRXValeant raises FY15 cash EPS view to $10.90-$11.20 from $10.10-$10.40
Subscribe for More Information
06:11 EDTVRXValeant sees Q2 cash EPS $2.40-$2.50, consensus $2.45
Subscribe for More Information
06:07 EDTVRXValeant reports Q1 cash EPS $2.36, consensus $2.34
Subscribe for More Information
April 28, 2015
10:19 EDTVRXPershing Square lists Herbalife, Actavis as top Q1 losers
Subscribe for More Information
07:43 EDTNSRGYMead Johnson pushing for changes to WIC program, WSJ reports
The law authorizing the $6B per year WIC program providing food vouchers to women who are pregnant or have young children is up for renewal this year and formula makers, led by top U.S. maker Mead Johnson (MJN), are pushing for change, said The Wall Street Journal. Growth in the program has made it a money-losing venture for baby formula makers who essentially make no profit off formula sold to states as part of the program and Mead Johnson is pushing for changing eligibility requirements, thereby limiting or even shrinking the pool of recipients, the report noted. Other U.S. infant formula makers include Abbott (ABT) and Nestle (NSRGY). Reference Link
April 27, 2015
06:19 EDTVRXPharmceutical companies buy drugs and raises prices, WSJ reports
Subscribe for More Information
April 24, 2015
09:18 EDTVRXValeant and Progenics' Relistor eceives positive opinion from EMA
Valeant (VRX) and Progenics (PGNX) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending a new indication for Relistor Subcutaneous Injection for the treatment of opioid-induced constipation when response to laxative therapy has not been sufficient in adult patients, aged 18 years and older. Additionally, the Committee has recommended a one-year extension of data/marketing protection for Relistor, to 11 years from the date of approval.
April 21, 2015
05:31 EDTLRLCYL'Oreal reports Q1 sales EUR 6.44B vs. EUR 5.64B
Subscribe for More Information
April 20, 2015
10:00 EDTLRLCYOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
05:39 EDTLRLCYL'Oreal downgraded to Neutral from Outperform at Credit Suisse
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use